Xenon制药 XENE 深 沪
等待开盘 05-20 09:30:00 美东时间
54.05
+0.340
+0.63%
华盛通- 最 高54.13
- 今 开53.52
- 成交量 85.28万股
- 最 低 52.85
- 昨 收 53.71
- 总市值 522.48万
- 52周最高 63.95
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 28.97
- 委 比 95.08%
- 总股本 9.67万
- 历史最高 63.95
- 量 比 0.94
- 振 幅 2.38%
- 历史最低 2.10
- 每 手 1
- 风险率 8.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Xenon Pharmaceuticals Maps Path After Standout XTOL-2
Xenon Pharmaceuticals (($XENE)) has held its Q1 earnings call. Read on for the ...
05-09 09:24
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $80 to $78.
05-08 19:36
财报速睇 | Xenon制药 2026财年Q1营收0.00亿美元，同比下降100.0%；归母净利润亏损1.02亿美元，同比亏损扩大57.3%
华盛资讯5月8日讯，Xenon制药公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比下降100.0%，归母净利润亏损1.02亿美元，同比亏损扩大57.3%。
05-08 09:32
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals reported first...
05-08 05:50
Xenon to Report Q1 2026 Financial Results on May 7, 2026
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced on April 30, 2026, that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, after U.S. market close. A live webcast and conference call will be held at 4:30pm ET (1:30pm PT), with details available on Xenon's investor website. The company, focused on neuroscience, is advancing azetukalner, a Phase 3 K<sub>V</sub>7 potassium channel open...
04-30 20:01
Reported Sunday, Xenon Presents Phase 3 X-TOLE2 Data Showing Azetukalner Delivers 53.2% Reduction In Monthly Seizure Frequency Versus 10.4% For Placebo In Focal Onset Seizures At AAN 2026
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in the Late-breaking Science session show 53.2% reduction in monthly seizure
04-20 16:34
